New epilepsy drug vormatrigine tested for Long-Term safety in 700 adults
NCT ID NCT07287163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the long-term safety of a once-daily drug called vormatrigine in 700 adults with focal or generalized tonic-clonic seizures. Participants must have already taken vormatrigine in a previous trial or program. The main goal is to check for side effects and changes in vital signs, not to measure how well the drug stops seizures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vormatrigine (a once-daily oral drug for seizures)
What this could lead to
If successful, this could confirm that vormatrigine is safe for long-term use and help control seizures in adults with epilepsy.
What could go wrong
This is an extension study focused on safety, not on proving the drug works. It only includes people who already tolerated the drug, so results may not apply to all patients. Side effects are still being monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEIZURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis Research Site
Miami Lakes, Florida, 33016, United States
-
Praxis Research Site
Naples, Florida, 34116, United States
-
Praxis Research Site
Lafayette, Louisiana, 70508, United States
-
Praxis Research Site
Bethesda, Maryland, 20817, United States
-
Praxis Research Site
Chesterfield, Missouri, 63005, United States
-
Praxis Research Site
Amherst, New York, 14226, United States
-
Praxis Research Site
Middletown, New York, 10941, United States
-
Praxis Research Site
El Paso, Texas, 79912, United States
-
Praxis Research Site
Houston, Texas, 77058, United States
-
Praxis Research Site
Bielefeld, 33617, Germany
-
Praxis Research Site
Tübingen, 72076, Germany
-
Praxis Research Site
Milan, 20133, Italy
-
Praxis Research Site
Pavia, 27100, Italy
-
Praxis Research Site
Bydgoszcz, 85163, Poland
-
Praxis Research Site
Katowice, 40123, Poland
-
Praxis Research Site
Barcelona, 08003, Spain
-
Praxis Research Site
Madrid, 28040, Spain
-
Praxis Research Site
Málaga, 29010, Spain
-
Praxis Research Site
Terrassa, 08222, Spain
-
Praxis Research Site
Valencia, 46026, Spain